Compared to previously dismal outcomes with a median survival of <1 year, studies of anti-PD-1 monotherapy and combination anti-CTLA-4/PD-1 therapy in advanced melanoma have reported 6.5-year-overall survival (OS) rates of 42% and 49%, respectively (Wolchok et al., 2022). This evidence concerns the gene CTLA4 and melanoma.